Gilead to buy cancer drugmaker Immunomedics for $21B

Gilead on Sunday reached a deal to buy Immunomedics for approximately $21 billion, agreeing to pay more than double the New Jersey drugmaker's market value to gain access to its recently approved breast cancer medicine.